CAL-51Homo sapiens (Human)Cancer cell line

Also known as: Centre Antoine Lacassagne-51, Cal51, CAL51, CAL 51, Ca151

🤖 AI SummaryBased on 11 publications

Quick Overview

Human cancer cell line for research on cancer biology and drug development.

Detailed Summary

CAL-51 is a human cancer cell line derived from an unspecified tissue and disease. It is used in research to study cancer biology, drug development, and genetic mutations. The cell line is part of large-scale studies that analyze genomic and transcriptomic data to identify potential therapeutic targets. Research on CAL-51 contributes to understanding cancer mechanisms and improving treatment strategies.
Generated on 6/16/2025

Basic Information

Database IDCVCL_1110
SpeciesHomo sapiens (Human)
Tissue SourcePleural effusion[UBERON:UBERON_0000175]

Donor Information

Age45
Age CategoryAdult
SexFemale
Subtype Featuresbasal_B TNBC

Disease Information

DiseaseBreast carcinoma
LineageBreast
SubtypeInvasive Breast Carcinoma
OncoTree CodeBRCA

DepMap Information

Source TypeDSMZ
Source IDACH-000856_source

Haplotype Information (STR Profile)

Short Tandem Repeat (STR) profile for cell line authentication.

Amelogenin
X
CSF1PO
11,12
D13S317
11,13
D16S539
11,13
D18S51
15,16,17
D19S433
12,14
D21S11
31,32
D2S1338
23,24
D3S1358
16,17
D5S818
12,13
D7S820
7,12
D8S1179
14
FGA
22,23
Penta D
10,14
Penta E
7,12
TH01
7
TPOX
8,9
vWA
18
Gene Expression Profile
Gene expression levels and statistical distribution
Loading cohorts...
Full DepMap dataset with combined data across cell lines

Loading gene expression data...

Publications

Pan-cancer proteomic map of 949 human cell lines.";

Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.

Cancer Cell 40:835-849.e8(2022).

Identification of cell lines CL-14, CL-40 and CAL-51 as suitable models for SARS-CoV-2 infection studies.

Safranko Z.M., Kurolt I.-C., Markotic A., Cicin-Sain L., Steenpass L.

PLoS ONE 16:E0255622-E0255622(2021).

Quantitative proteomics of the Cancer Cell Line Encyclopedia.";

Sellers W.R., Gygi S.P.

Cell 180:387-402.e16(2020).

Next-generation characterization of the Cancer Cell Line Encyclopedia.

Sellers W.R.

Nature 569:503-508(2019).

Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens.

Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.

Nature 568:511-516(2019).

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.

Cancer Res. 79:1263-1273(2019).

Characterization of human cancer cell lines by reverse-phase protein arrays.

Liang H.

Cancer Cell 31:225-239(2017).

A landscape of pharmacogenomic interactions in cancer.";

Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.

Cell 166:740-754(2016).

TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.

Loewer M., Sahin U., Castle J.C.

Genome Med. 7:118.1-118.7(2015).

Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies.

Golub T.R., Root D.E., Hahn W.C.

Sci. Data 1:140035-140035(2014).

A resource for cell line authentication, annotation and quality control.

Neve R.M.

Nature 520:307-311(2015).

A comprehensive transcriptional portrait of human cancer cell lines.

Settleman J., Seshagiri S., Zhang Z.-M.

Nat. Biotechnol. 33:306-312(2015).

Modeling precision treatment of breast cancer.";

Collisson E.A., van 't Veer L.J., Spellman P.T., Gray J.W.

Genome Biol. 14:R110.1-R110.14(2013).

Loss of O(6)-methylguanine-DNA methyltransferase confers collateral sensitivity to carmustine in topoisomerase II-mediated doxorubicin resistant triple negative breast cancer cells.

Cazzanelli G., Zhou Y., Patel N., Coombes R.C., Yague E.

Biochem. Pharmacol. 85:186-196(2013).

Essential gene profiles in breast, pancreatic, and ovarian cancer cells.

Rottapel R., Neel B.G., Moffat J.

Cancer Discov. 2:172-189(2012).

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.

Nature 483:603-607(2012).

Triple negative breast cancer cell lines: one tool in the search for better treatment of triple negative breast cancer.

Chavez K.J., Garimella S.V., Lipkowitz S.

Breast Dis. 32:35-48(2010).

A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.

Haber D.A.

Cancer Res. 70:2158-2164(2010).

Signatures of mutation and selection in the cancer genome.";

Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.

Nature 463:893-898(2010).

Molecular profiling of breast cancer cell lines defines relevant tumor models and provides a resource for cancer gene discovery.

Pollack J.R.

PLoS ONE 4:E6146-E6146(2009).

Evidence that both genetic instability and selection contribute to the accumulation of chromosome alterations in cancer.

Edwards P.A.W., Caldas C.

Carcinogenesis 26:923-930(2005).

A recurrent chromosome translocation breakpoint in breast and pancreatic cancer cell lines targets the neuregulin/NRG1 gene.

Edwards P.A.W., Chaffanet M.

Genes Chromosomes Cancer 37:333-345(2003).

Identification of microsatellite instability and mismatch repair gene mutations in breast cancer cell lines.

Santibanez-Koref M.F., Schlag P.M., Scherneck S.

Genes Chromosomes Cancer 37:29-35(2003).

Molecular cytogenetic analysis of breast cancer cell lines.";

Courtay-Cahen C., Roberts I., Theillet C., Caldas C., Edwards P.A.W.

Br. J. Cancer 83:1309-1317(2000).

Comparative genomic hybridization analysis of 38 breast cancer cell lines: a basis for interpreting complementary DNA microarray data.

Gooden G.C., Ethier S.P., Kallioniemi A.H., Kallioniemi O.-P.

Cancer Res. 60:4519-4525(2000).

Establishment and characterisation of a new tumorigenic cell line with a normal karyotype derived from a human breast adenocarcinoma.

Lambert J.-C., Schneider M., Dutrillaux B.

Br. J. Cancer 62:8-13(1990).